Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Healthcare Biotechnology
Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Allon Therapeutics Inc > Takacsy
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5973)
•••
Comment by retiredcfon Jun 26, 2017 3:46pm
190 Views
Post# 26406636

RE:Takacsy

RE:Takacsy
2017-06-26 BUY Stephen Takacsy, B. Eng, MBA
 
They had very good results last quarter, but it is still a ‘show me’ story to a lot of people.  There are big investors accumulating in the name.  If management delivers on promises the stock price should go a lot higher.
 
Login to show your approval   Login to show your disapproval / Be the first to comment
Price:
$1.11
Subject:
CANADIAN
Bias:
SELECTIVE
Owned:
Yes
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities